









Markets
/
Stocks
/
nasdaq-nktr
/

Nektar Therapeutics

NKTR

59.920USD

-5.010-7.72%

Close 11/03, 16:00（ET）Quotes delayed by 15 min

746.44MMarket Cap

LossP/E TTM



Nektar Therapeutics

59.920

-5.010-7.72%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Nektar Therapeutics

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Nektar Therapeutics's Score

Industry at a Glance

Industry Ranking

112 / 407

Overall Ranking

234 / 4617

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

93.180

Target Price

+43.51%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Nektar Therapeutics Highlights

StrengthsRisks

Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Growing

The company is in a growing phase, with the latest annual income totaling USD 98.43M.

Undervalued

The company’s latest PE is -6.95, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 9.78M shares, decreasing 19.39% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 1.10K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.66.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 5.53, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 11.18M, representing a year-over-year decrease of 52.42%, while its net profit experienced a year-over-year decrease of 20.57%.

Score

Industry at a Glance

Previous score

5.53

Change



Financials

4.81

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.79

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.37

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Nektar Therapeutics's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 6.87, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -6.95, which is -99.77% below the recent high of -0.02 and -8.36% above the recent low of -7.53.

Score

Industry at a Glance

Previous score

6.87

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 112/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Nektar Therapeutics is 100.00, with a high of 115.26 and a low of 30.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Buy

Current Rating

93.180

Target Price

+43.51%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Nektar Therapeutics

NKTR

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 7.63, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 66.92 and the support level at 52.91, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.65

Change

-2.02

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.793

Neutral

RSI(14)

53.007

Neutral

STOCH(KDJ)(9,3,3)

48.818

Sell

ATR(14)

5.045

High Vlolatility

CCI(14)

-5.513

Neutral

Williams %R

53.071

Neutral

TRIX(12,20)

0.589

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

61.640

Sell

MA10

61.567

Sell

MA20

59.365

Buy

MA50

52.298

Buy

MA100

37.423

Buy

MA200

19.227

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 51.45%, representing a quarter-over-quarter decrease of 3.94%. The largest institutional shareholder is The Vanguard, holding a total of 948.65K shares, representing 4.99% of shares outstanding, with 25.37% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BVF Partners L.P.

1.28M

The Vanguard Group, Inc.

Star Investors

729.49K

-11.11%

Nantahala Capital Management, LLC

709.76K

+36.68%

Millennium Management LLC

649.03K

+325.35%

Emerald Advisers LLC

143.29K

+0.27%

AQR Capital Management, LLC

427.87K

+76.28%

Acadian Asset Management LLC

420.96K

-13.52%

Balyasny Asset Management LP

386.29K

+581.60%

PRIMECAP Management Company

Star Investors

299.72K

-16.04%

BlackRock Institutional Trust Company, N.A.

297.81K

-65.92%

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 4.30, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.20. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.